Summit Therapeutics (SMMT) Change in Receivables (2017 - 2023)

Summit Therapeutics (SMMT) has 7 years of Change in Receivables data on file, last reported at -$3000.0 in Q3 2023.

• Quarterly Change in Receivables rose 99.76% year-over-year to -$3000.0 in Q3 2023, while the trailing twelve-month figure through Dec 2024 was -$0.0 (up 100.0% YoY) and the FY2023 annual result came in at -$359000.0, up 63.18% from the prior year.
• Change in Receivables rose to -$3000.0 in Q3 2023, from -$6000.0 in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $8.1 million in Q4 2019 to a low of -$3.7 million in Q4 2020.
• A 5-year average of $451387.2 and a median of -$6000.0 in 2023 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2020 — Change in Receivables surged 3290.27% — and 2022, when it sank 499.12%.
• Tracing SMMT's Change in Receivables over 5 years: stood at $8.1 million in 2019, then tumbled by 145.46% to -$3.7 million in 2020, then surged by 74.76% to -$932000.0 in 2021, then jumped by 251.5% to $1.4 million in 2022, then tumbled by 100.21% to -$3000.0 in 2023.
• The last three Change in Receivables figures came in at -$3000.0 (Q3 2023), -$6000.0 (Q2 2023), and -$350000.0 (Q1 2023), per Business Quant data.